JP2022517797A5 - - Google Patents
Info
- Publication number
- JP2022517797A5 JP2022517797A5 JP2021541215A JP2021541215A JP2022517797A5 JP 2022517797 A5 JP2022517797 A5 JP 2022517797A5 JP 2021541215 A JP2021541215 A JP 2021541215A JP 2021541215 A JP2021541215 A JP 2021541215A JP 2022517797 A5 JP2022517797 A5 JP 2022517797A5
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- alkyl
- group
- substituted
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962793623P | 2019-01-17 | 2019-01-17 | |
| US62/793,623 | 2019-01-17 | ||
| US201962861702P | 2019-06-14 | 2019-06-14 | |
| US62/861,702 | 2019-06-14 | ||
| PCT/US2020/013824 WO2020150439A1 (en) | 2019-01-17 | 2020-01-16 | Compounds and compositions for treating conditions associated with sting activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022517797A JP2022517797A (ja) | 2022-03-10 |
| JP2022517797A5 true JP2022517797A5 (enExample) | 2023-01-20 |
Family
ID=69593778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541215A Pending JP2022517797A (ja) | 2019-01-17 | 2020-01-16 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220388957A1 (enExample) |
| EP (1) | EP3911314A1 (enExample) |
| JP (1) | JP2022517797A (enExample) |
| CN (1) | CN113874010A (enExample) |
| MA (1) | MA54753A (enExample) |
| WO (1) | WO2020150439A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120004785A (zh) | 2018-07-03 | 2025-05-16 | 诺华制药股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| CN112375027B (zh) * | 2020-12-07 | 2023-03-31 | 中国药科大学 | 吲哚磺酰胺类衍生物及其医药用途 |
| EP4267129A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4267128A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| JP2024500874A (ja) | 2020-12-22 | 2024-01-10 | アイエフエム デュー インコーポレイテッド | がんを処置する方法 |
| US20240060982A1 (en) * | 2020-12-22 | 2024-02-22 | Ifm Due, Inc. | Methods of treating cancer |
| EP4274824A1 (en) | 2021-01-08 | 2023-11-15 | IFM Due, Inc. | Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity |
| IL310724A (en) | 2021-08-10 | 2024-04-01 | Ifm Due Inc | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY |
| CR20250058A (es) * | 2022-08-26 | 2025-05-09 | Hoffmann La Roche | Derivados novedosos deuterados de pirimidin-2-il sulfonamida |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2074163A1 (en) * | 1990-01-22 | 1991-07-23 | William Thomas Zimmerman | Herbicidal sulfonylureas |
| US6521658B1 (en) * | 1999-05-28 | 2003-02-18 | Abbott Laboratories | Cell proliferation inhibitors |
| US6646009B2 (en) * | 2001-02-28 | 2003-11-11 | Temple University — Of Commonwealth System of Higher Education | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| RU2337909C2 (ru) * | 2002-02-01 | 2008-11-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7390670B2 (en) * | 2003-02-20 | 2008-06-24 | Lumigen, Inc. | Signalling compounds and methods for detecting hydrogen peroxide |
| NZ579892A (en) * | 2007-03-30 | 2012-03-30 | Sanofi Aventis | Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors |
| US8497285B2 (en) | 2010-12-03 | 2013-07-30 | The Trustees Of The University Of Pennsylvania | Therapy of autoimmune colitis using a TIP60 inhibitor |
| CA2927009C (en) | 2013-10-21 | 2019-04-23 | Drexel University | Use of sting agonists to treat chronic hepatitis b virus infection |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| AR106018A1 (es) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017153952A1 (en) * | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| US10858344B2 (en) * | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| TWI754702B (zh) * | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
| CN120004785A (zh) * | 2018-07-03 | 2025-05-16 | 诺华制药股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| JP7482122B2 (ja) * | 2018-07-03 | 2024-05-13 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| JP2022507697A (ja) * | 2018-11-19 | 2022-01-18 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| WO2020252240A1 (en) * | 2019-06-14 | 2020-12-17 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2020254289A1 (en) * | 2019-06-17 | 2020-12-24 | Ucb Pharma Gmbh | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis |
| CN114761804A (zh) * | 2019-06-21 | 2022-07-15 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
-
2020
- 2020-01-16 JP JP2021541215A patent/JP2022517797A/ja active Pending
- 2020-01-16 CN CN202080021980.7A patent/CN113874010A/zh active Pending
- 2020-01-16 MA MA054753A patent/MA54753A/fr unknown
- 2020-01-16 EP EP20705838.9A patent/EP3911314A1/en not_active Withdrawn
- 2020-01-16 US US17/422,397 patent/US20220388957A1/en not_active Abandoned
- 2020-01-16 WO PCT/US2020/013824 patent/WO2020150439A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517797A5 (enExample) | ||
| JP2022507697A5 (enExample) | ||
| JP2023509421A5 (enExample) | ||
| JP2021529833A5 (enExample) | ||
| JP2021529834A5 (enExample) | ||
| JP7261379B2 (ja) | 抗ｐｄ－ｌ１抗体 | |
| US10973915B2 (en) | Anti-PD-1 antibodies and uses thereof | |
| JP7046973B2 (ja) | 抗ｏｘ４０抗体およびその使用 | |
| US10889648B2 (en) | Anti-PD-L1 antibodies and uses thereof | |
| JP7290568B2 (ja) | 癌免疫療法のための併用療法での多重特異性抗体 | |
| WO2019089969A2 (en) | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen | |
| WO2019030377A1 (en) | CD96 BINDING AGENTS AS IMMUNOMODULATORS | |
| EP2785736A2 (en) | Assays, antibodies, immunogens and compositions related to 5-fu | |
| CN108699000B (zh) | 用于抑制趋化因子活性及/或癌细胞生长的小分子 | |
| JP7059389B2 (ja) | 抗ｐｄ－１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| JP7059388B2 (ja) | 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| HK40036544A (en) | Cd96-binding agents as immunomodulators |